stella
beta
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma — Stella
Recruiting
Back to Melanoma trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Beijing Cancer Hospital, Beijing, Beijing Municipality
View full record on ClinicalTrials.gov